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LETTER TO THE EDITOR
Strengths of breath-triggered
inhalers in asthma management
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devices.  The  ease  of  use  of  BAIs  may  offer  particular  advan-
tages  in  certain  patient  groups,  such  as  children,  the  elderly
or  those  with  limited  manual  dexterity.4,5 BAIs  that  are
Table  1  Breath-actuated  inhalers:  key  advantages  and
disadvantages.
Advantages  Disadvantages
Portable  and  compact
• Multi-dose  device
• High  reproducibility  in  the
amount  of  drug  delivered
•  Closed  canister,  so  contents
cannot  be  contaminated
Benefits  over  conventional
pMDIs
-- No  need  to  coordinate
inhalation  and  actuation
Benefits  over  DPIs
•  Available  for  a  limited
range  of  drugs
•  Suspension
formulations  need  to  be
shaken  before  each  use
•  Important  to  prime
before  first  use,  if  not
used  for  some  time  or  if
the  inhaler  has  been
exposed  to  cold
temperaturesDear  Editor,
Asthma  affects  the  lives  of  several  hundred  million  people
around  the  World,  across  all  age  groups  and  Portugal  is  not
an  exception,  with  an  asthma  lifetime  prevalence  of  10.5%.1
Patients,  their  families  and  the  society  face  high  direct
and  indirect  costs,  due  to  healthcare  resources  use,  loss
of  productivity,  absenteeism  and  presenteeism  of  patients.
Asthma  strongly  influences  the  wellbeing  and  quality  of
life  of  patients.  With  no  established  curative  treatment,
guidelines  for  asthma  management  have  identified  that  the
primary  goal  of  management  is  to  achieve  asthma  control.2
In  asthma,  pharmacological  treatments  mainly  consist  of
inhaled  drugs,  which  allow  efficacy  and  significantly  reduce
systemic  side  effects,  being  the  most  efficacious  treat-
ments.  However,  lack  of  adherence  to  treatment  in  asthma
occurs  in  more  than  half  of  all  medical  prescriptions.  Fur-
thermore,  reduced  adherence  to  treatment  frequently  allies
with  an  incorrect  inhalation  technique,  both  considered
major  issues  significantly  impairing  pharmacologic  treat-
ments  effectiveness.  Therefore,  despite  the  efficacy  of  the
available  drugs,  a  high  percentage  of  asthmatics  are  uncon-
trolled  and  have  frequent  exacerbations.
Difficulties  in  using  inhalation  methods  are  well-known
problems  that  have  been  consistently  maintained  in  recent
decades,  with  the  occurrence  of  several  errors  that  affect
treatment  results  with  the  use  of  both  dry  powder  inhalers
(DPIs)  and  pressurized  metered-dose  inhalers  (pMDIs).
Results  from  the  Critikal  study3 analyses  of  the  inhaler
technique  assessment  initiative  Helping  Asthma  in  Real-life
Patients  (iHARP)  database  have  helped  to  identify  the  preva-
lence  of  critical  inhaler  errors  (those  that  have  a  definite
detrimental  impact  on  the  delivery  of  drug  to  the  lungs)
with  different  devices  in  patients  with  asthma.  The  most
common  critical  errors  included  failure  to  coordinate  device
actuation  and  inhalation  with  pMDIs,  and  lack  of  a  force-
ful  inhalation  with  DPIs;  overall,  89%  of  patients  made  at
least  one  potentially  critical  handling  error  and  67%  made
multiple  potentially  critical  errors.3Please  cite  this  article  in  press  as:  Morais-Almeida  M,  et  al.  Stre
Pulmonol.  2020.  https://doi.org/10.1016/j.pulmoe.2020.04.01
Breath-actuated  inhalers  (BAIs)  represented  an  evolution
in  inhalers’  design  aiming  to  improve  the  management  of
asthma.4 BAIs  are  aerosol  devices,  like  pMDIs,  but  rather
than  being  activated  manually,  they  automatically  release
https://doi.org/10.1016/j.pulmoe.2020.04.015
2531-0437/© 2020 Sociedade Portuguesa de Pneumologia. Published by 
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)ion  when  chlorofluorocarbon  propellants  (CFCs)  were  used
nd  the  speed  of  emission  of  the  aerosol  was  so  high  that  the
mpact  of  inhaled  droplets  in  the  upper  airways  was  still  very
ignificant;  nowadays,  with  hydrofluoroalkane  propellants
HFAs),  the  speed  of  emission  is  considerably  lower  and  the
erosol  may  be  inhaled  slowly  being  deposited  more  periph-
rally  in  the  airways.  These  new  devices  may  offer  several
dvantages  (Table  1),  and  were  developed  to  overcome  the
ost  commonly  seen  critical  errors  with  other  inhalers,  as
ollows:  there  is  no  need  to  coordinate  actuation  and  inhala-
ion  (which  is  necessary  for  pMDIs);  as  active  devices,  BAIs
mit  a  propelled  aerosol  and  patients  do  not  need  to  inhale
orcibly  to  generate  respirable  particles  (which  is  required
or  DPIs).4,5
BAIs  are  intended  to  simplify  the  inhaler  technique,  lead-
ng  to  improved  inhaler  use  by  the  patients  and  less  health
are  professional  (HCP)  time  spent  training  patients  to  use
he  devices  correctly.4 Indeed,  several  studies  have  shown
hat  patients  find  BAIs  easier  to  use  and  HCP  find  it  eas-
er  to  train  patients  in  their  correct  use  in  relation  to  otherngths  of  breath-triggered  inhalers  in  asthma  management.
5
-- Releases  drug  at  low
inspiratory  force,  so  no  need  to
inhale  forcibly
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Table  2  Key  attributes  of  the  breath-triggered  k-haler®.
General  design
Minimal  inhalation  force  is  required  to
trigger  the  device
•  Ensures  that  a  dose  is  released  even  if  the  patient  has  limited  lung  capacity
and gives  a  ‘nice  feel’  upon  actuation
Shape •  Retains  the  classic  ‘pMDI’  shape  familiar  to  patients;  the  size  and  shape  of
DPIs vary  considerably,  which  can  lead  to  patient  confusion
Orange translucent  cap  and  silver
detailing
•  Helps  patients  to  orientate  the  inhaler  correctly  and  to  identify  the
mouthpiece  correctly
Small, compact  size •  Easy  to  store  and  carry,  and  fits  nicely  in  the  hand  (even  small  hands)
• Can  be  used  discreetly  and  has  a  comfortable  fit  in  the  mouth
Closed system  •  Prevents  dirt  and  dust  from  accumulating  in  the  inhaler  that  could  clog  the
device and  irritate  patients’  airways
Usability
Open--breathe--close  operation  •  Few  simplified  steps  are  required  to  prime  and  operate  the  device
Cap is  connected  to  the  device  •  The  cap  cannot  be  lost  and  can  be  repositioned  easily  when  priming/closing
Dose feedback
Easy-to-read  dose  counter  in  font
designed  specifically  by  the  UK  Royal
National  Institute  for  the  Blind
•  Ensures  that  patients  know  how  many  doses  are  left
Audible ‘clicks’  when  dosing  and  when
closing
•  Feedback  that  the  device  is  primed  and  ready  for  use  and  also  when  the  cap
has been  closed  securely
Automatic  release  of  dose  when  the
mouthpiece  cap  is  closed  if  a  primed
•  Alerts  the  patient  that  a  dose  has  not  been  taken


















































dose  is  not  taken
riggered  by  a  low  inspiratory  force  may  offer  additional
dvantage.4
An  ergonomically  designed  breath-triggered  inhaler
BTI),  k-haler®,5 was  recently  available.  Its  successful  use
nvolves  only  a  few  steps  and,  as  an  ‘active’  aerosol  inhaler,
t  automatically  releases  a  dose  of  the  drug  in  a  respirable
orm  when  a  patient  inhales,  even  at  a  low  inspiratory
ow  (the  device  is  triggered  at  an  inspiratory  flow  rate  of
pproximately  30  L/min).  A  high  fine  particle  fraction  and
 plume  that  is  less  forceful  than  that  of  previous  pMDIs
an  decrease  drug  impaction  at  the  back  of  the  throat  and
mprove  delivery  to  the  lungs.5 As  such,  k-haler® represents
n  added-value  to  improve  asthma  control  by  addressing
urrent  patients’  needs  and  overcoming  the  most  common
asting  critical  errors  referred  with  other  inhalers  (Table  2).5
The  simplicity  of  use,  better  inhaler  handling  and  patient
reference  for  BAIs  are  advantages  that  may  translate  into
mproved  treatment  compliance  with  the  prescribed  ther-
py,  leading  to  improved  lung  function  and  asthma  control
ompared  with  other  devices.4--6 Several  controlled  stud-
es  comparing  the  efficacy  of  drugs  at  equivalent  nominal
oses  administered  with  different  devices  had  demonstrated
quivalence  in  the  main  clinical  outcomes  (mostly  symp-
oms  and  exacerbations)  of  asthma  (or  chronic  obstructive
ulmonary  disease),  but  this  may  be  justified  by,  1.  the
arge  number  of  variables  affecting  the  clinical  response
o  inhaled  drugs,  besides  the  inhalation  technique  and  2.
he  gap  between  the  patients  in  clinical  trial  conditions  in
eferral  centers  with  specific  characteristics  and  close  mon-Please  cite  this  article  in  press  as:  Morais-Almeida  M,  et  al.  Stre
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toring,  being  aware  that  they  are  being  evaluated,  and
hose  patients  in  the  real  world,  where  poor  inhalation  tech-
ique  and  low  adherence  to  therapy  are  known  to  be  more
ommon.3--7
1
If  correctly  and  effectively  used,  inhalers  are  excellent,
afe  and  effective  in  controlling  asthma,  as  in  other  chronic
espiratory  diseases.7 Improving  inhalers  correct  and  effec-
ive  use  is  therefore  a  global  issue  to  overcome  current
nown  difficulties  and  to  move  forward  into  achieving  higher
ates  of  asthma  control.
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